首页> 外文期刊>BMC Public Health >Relationship between combination antiretroviral therapy regimens and diabetes mellitus-related comorbidities among HIV patients in Gaborone Botswana
【24h】

Relationship between combination antiretroviral therapy regimens and diabetes mellitus-related comorbidities among HIV patients in Gaborone Botswana

机译:博茨瓦纳哈博罗内艾滋病毒感染者联合抗逆转录病毒治疗方案与糖尿病相关合并症的关系

获取原文
       

摘要

Combination antiretroviral therapy (cARTs) regiments are known to prolong the recipients’ life even though they are risk factors for diabetes mellitus-related comorbidities (DRCs). We sought to: (i) examine cART relationship with DRCs among patients attending HIV clinics in Gaborone, Botswana (which cART regimens are associated with shorter/longer time to the event), (ii) characterize patients’ underlying biomedical and demographic risk factors of DRC and identify the most important, (iii) investigate survival of patients on different cART regimens in the presence of these risk factors. Data from two major HIV clinics in Botswana were reviewed. Relationships between different cART regimens and DRCs were investigated among 531 recipients. Recipients’ DRC risk factors were identified. Cox regression model was run. Unadjusted and adjusted hazard ratios were computed, and hazard and survival functions for different cART regimens were plotted. Major findings were: patients on second- and third-line cART were less likely to develop DRCs earlier than those on first-line cART. Patients with CD4 count ≤?200 cells/mm3 at cART initiation were more likely to develop DRCs earlier than those who had CD4 count >?200 cells/mm3. Overweight patients at cART initiation had a higher risk of developing DRCs earlier than those who had normal body mass index. Males had a lower risk of developing DRCs earlier than females. The risk of new onset of DRC among cART recipients is a function of the type of cART regimen, duration of exposure and patients’ underlying biomedical and demographic DRC risk factors. The study has provided a survival model highlighting DRCs’ significant prognostic factors to guide clinical care, policy and management of recipients of cARTs. Further studies in the same direction will likely improve the survival to the development of DRC of every cART recipient in this community.
机译:已知联合抗逆转录病毒疗法(cARTs)可以延长受体的寿命,即使它们是糖尿病相关合并症(DRC)的危险因素。我们力图:(i)在博茨瓦纳哈博罗内HIV诊所就诊的患者中检查cART与DRC的关系(cART方案与事件发生时间的长短相关);(ii)表征患者潜在的生物医学和人口统计学危险因素DRC并确定最重要的指标;(iii)在存在这些危险因素的情况下,调查采用不同cART方案的患者的生存率。审查了来自博茨瓦纳两个主要艾滋病诊所的数据。在531位接受者中调查了不同cART方案与DRC之间的关系。确定了收件人的DRC风险因素。运行Cox回归模型。计算了未调整和调整后的危险比,并绘制了不同cART方案的危险和生存函数。主要发现是:与一线cART相比,二线和三线cART患者较早出现DRC的可能性较小。在cART启动时,CD4计数≤200细胞/ mm3的患者比CD4计数≥200细胞/ mm3的患者更容易出现DRC。在开始cART时,超重患者比正常体重指数的患者更早出现DRC的风险。男性患DRC的风险比女性低。 cART接受者中DRC新发的风险取决于cART方案的类型,接触时间和患者潜在的生物医学和人口统计学DRC危险因素。这项研究提供了一个生存模型,突出了DRC的重要预后因素,以指导cART接受者的临床护理,政策和管理。在同一方向上的进一步研究可能会改善该社区中每个cART接受者发展DRC的存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号